ResMed (RMD) Projected to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is anticipated to release its Q4 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $2.90 per share and revenue of $1.4613 billion for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping the consensus estimate of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.42 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The firm’s revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.37 earnings per share. On average, analysts expect ResMed to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

ResMed Stock Performance

NYSE RMD opened at $214.36 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. ResMed has a 1-year low of $180.26 and a 1-year high of $293.81. The firm has a market capitalization of $31.09 billion, a P/E ratio of 20.67, a P/E/G ratio of 1.27 and a beta of 0.78. The business’s 50-day simple moving average is $198.80 and its 200-day simple moving average is $223.98.

Insider Activity at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $101,893,036.65. The trade was a 1.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 14,973 shares of company stock valued at $3,096,067. 0.65% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ResMed

Hedge funds have recently added to or reduced their stakes in the business. WFA of San Diego LLC bought a new stake in ResMed during the second quarter valued at $26,000. Imprint Wealth LLC acquired a new stake in shares of ResMed during the third quarter worth $26,000. Sunbelt Securities Inc. bought a new position in shares of ResMed in the 3rd quarter worth about $31,000. DV Equities LLC bought a new position in shares of ResMed in the 4th quarter worth about $49,000. Finally, Kelleher Financial Advisors bought a new position in shares of ResMed in the 3rd quarter worth about $66,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wells Fargo & Company cut their price target on shares of ResMed from $227.00 to $225.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. Morgan Stanley reissued an “equal weight” rating and issued a $230.00 price objective (down from $286.00) on shares of ResMed in a research report on Wednesday, June 17th. Evercore set a $255.00 target price on shares of ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. Jefferies Financial Group dropped their target price on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday, July 10th. Finally, Weiss Ratings lowered shares of ResMed from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average target price of $246.25.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.